O. Rixe
Impact in
- Oncology top 10%
- Cancer Treatment and Pharmacology
- HER2/EGFR in Cancer Research
- Colorectal Cancer Treatments and Studies
-
- Breast Cancer Treatment Studies
- Cancer Genomics and Diagnostics
Papers in
- Oncology 10
- Cancer Treatment and Pharmacology 4
- HER2/EGFR in Cancer Research 3
-
- Renal cell carcinoma treatment 2
- Lung Cancer Treatments and Mutations 2
- Gastric Cancer Management and Outcomes 2
- Co-authors
- James J. Driscoll (1 shared paper)M. Riofrio (1 shared paper)Karim Fizazi (1 shared paper)Laurent Zelek (1 shared paper)M. Spielmann (1 shared paper)A. Le Cesne (1 shared paper)J.P. Delord (1 shared paper)S. Barthier (1 shared paper)
- Journals
- Journal of Clinical Oncology (7 papers)European Journal of Cancer (1 paper)Cancer (1 paper)The Cancer Journal (1 paper)Cancer Research (1 paper)
- Partner nations
- FranceUnited StatesChina
In The Last Decade
O. Rixe
15 papers receiving 480 citations
Peers
Comparison fields: 5 of 54
- Oncology 299
- Cancer Research 110
- Pulmonary and Respiratory Medicine 88
- Dermatology 20
- Statistics and Probability 14
Countries citing papers authored by O. Rixe
This map shows the geographic impact of O. Rixe's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by O. Rixe with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites O. Rixe more than expected).
Fields of papers citing papers by O. Rixe
This network shows the impact of papers produced by O. Rixe. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by O. Rixe. The network helps show where O. Rixe may publish in the future.
Co-authors
The 25 scholars most cited alongside O. Rixe, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
| # | Work | ||
|---|---|---|---|
| 1 | 2010 | 178 | |
| 2 | 2001 | 122 | |
| 3 | 2009 | 112 | |
| 4 | 2007 | 15 | |
| 5 | 2008 | 14 | |
| 6 | 2007 | 12 | |
| 7 | 2006 | 12 | |
| 8 | 2008 | 7 | |
| 9 | 2004 | 5 | |
| 10 | Preliminary results of a phase I/II study of paclitaxel, cisplatin, and cyclophosphamide in advanced ovarian carcinoma. | 1997 | 4 |
| 11 | [Adjuvant therapy of surgically removed stage I melanoma]. | 1995 | 2 |
| 12 | 2001 | 2 | |
| 13 | 2012 | 1 | |
| 14 | 2007 | 1 | |
| 15 | 2006 | 1 | |
| 16 | 2005 | 0 |
About O. Rixe
O. Rixe is a scholar working on Oncology, Pulmonary and Respiratory Medicine, Reproductive Medicine, Molecular Biology and Radiology, Nuclear Medicine and Imaging, having authored 16 papers that have together received 488 indexed citations. Recurring topics across this work include Cancer Treatment and Pharmacology (4 papers), Ovarian cancer diagnosis and treatment (4 papers), HER2/EGFR in Cancer Research (3 papers), Angiogenesis and VEGF in Cancer (2 papers), Renal cell carcinoma treatment (2 papers), Lung Cancer Treatments and Mutations (2 papers), Gastric Cancer Management and Outcomes (2 papers) and Intraperitoneal and Appendiceal Malignancies (1 paper). The work is most often cited by research in Oncology (299 citations), Cancer Research (110 citations), Pulmonary and Respiratory Medicine (88 citations), Dermatology (20 citations) and Statistics and Probability (14 citations). O. Rixe has collaborated with scholars based in France, United States and China. Frequent co-authors include James J. Driscoll, M. Riofrio, Karim Fizazi, Laurent Zelek, M. Spielmann, A. Le Cesne, J.P. Delord, S. Barthier, Alexey Manikhas and Ronald Peck. Their work appears in journals such as Journal of Clinical Oncology, European Journal of Cancer, Cancer, The Cancer Journal and Cancer Research.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.